Đánh giá hiệu quả và tính an toàn của Imatinib trong điều trị bước một đối với bướu mô đệm đường tiêu hóa di căn=Assessment of efficiency and safety of Imatinib in the first line treatment of metastatic gastrointestinal stromal tumor

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Ngọc Quỳnh Như Hồ, Hoàng Quý Nguyễn, Thị Hồng Đức Phan, Ngọc Huân Võ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.169-177

Bộ sưu tập: Báo, Tạp chí

ID: 246433

Thêm vào giỏ

Đánh giá tỉ lệ đáp ứng, tỉ lệ kiểm soát bệnh, thời gian sống còn bệnh không tiến triển, sống còn toàn bộ và một số độc tính của Imatinib trong điều trị bước một trên bệnh nhân bướu mô đệm đường tiêu hóa giai đoạn di căn tại khoa Nội Tuyến vú, Tiêu hóa, Gan niệu Bệnh viện Ung Bướu TPHCM. Đối tượng và phương pháp nghiên cứu: Nghiên cứu hồi cứu mô tả trên nhóm bệnh nhân chẩn đoán bướu mô đệm đường tiêu hóa giai đoạn di căn, có chỉ định điều trị Imatinib tại khoa Nội Tuyến vú, Tiêu hóa, Gan niệu Bệnh viện Ung Bướu TPHCM từ tháng 01/2021 đến tháng 12/2022 Kết quả: Tỉ lệ đáp ứng: 10,3%, tỉ lệ kiểm soát bệnh: 72,4%, chưa ghi nhận thời gian trung vị PFS và OS nhưng tỉ lệ sống còn bệnh không tiến triển 2 năm: 70%, tỉ lệ sống còn toàn bộ 2 năm: 92%. Các độc tính ghi nhận bao gồm: phù ngoại vi (13,7%), mệt mỏi (10,3%), tiêu chảy (3,4%) và các độc tính này chủ yếu là độ 1. Kết luận: Imatinib trong điều trị bước 1 đối với nhóm bệnh nhân bướu mô đệm đường tiêu hóa giai đoạn di căn có tỉ lệ kiểm soát bệnh tốt, độc tính dung nạp được.To assess the effects of imatinib in first line treatment of metastatic gastrointestinal stromal tumor by response rate, disease control rate, progression free survival, overall survival and side effect of drug at Medical Oncology of Breast, Gastroenterology, Hepatology and Urology Department of Oncology Hospital Subject and method: Retrospective caseseries study on patients diagnosed with metastatic gastrointestinal stromal tumor at Medical Oncology of Breast, Gastroenterology, Hepatology and Urology Department of Oncology Hospital from 01/2021 to 12/2022. Results: The response rate is 10.3%, the disease control rate is 72.4%, the median time of PFS and OS was not recorded but the 2-year progression-free survival rate is 70%, the 2-year overall survival rate is 92%. The toxicities are edema (13.7%), fatigue (10.3%), diarrhea (3.4%), but all are in grade 1. Conclusion: Imatinib in the first-line treatment of patients with metastatic gastrointestinal stromal tumors has good disease control rates and tolerable toxicity.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR